Last reviewed · How we verify
Risk of seizure — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Risk of seizure (Risk of seizure) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Risk of seizure TARGET | Risk of seizure | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Risk of seizure CI watch — RSS
- Risk of seizure CI watch — Atom
- Risk of seizure CI watch — JSON
- Risk of seizure alone — RSS
Cite this brief
Drug Landscape (2026). Risk of seizure — Competitive Intelligence Brief. https://druglandscape.com/ci/risk-of-seizure. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab